Featured Research

from universities, journals, and other organizations

New myeloma drug shows promise in early testing

Date:
June 9, 2010
Source:
University of Michigan Health System
Summary:
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.

A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.

A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism. The early stage trial combined elotuzumab with bortezomib, or Velcade, one of the novel chemotherapies approved to treat multiple myeloma, a cancer that arises in the plasma cells.

"Elotuzumab was found to work in synergy with bortezomib in a pre-clinical model, which served as the basis for this clinic trial. The regimen was well-tolerated, and many patients stayed on it for a long time," says Andrzej Jakubowiak, M.D., Ph.D., director of the Multiple Myeloma Program at the University of Michigan Comprehensive Cancer Center. Jakubowiak presented results of the study at the American Society of Clinical Oncology annual meeting.

The study looked at 28 patients with multiple myeloma that had relapsed or become unresponsive to treatment. Overall, 48 percent responded to the elotuzumab and bortezomib combination and patients' cancer progressed after an average 9.45 months. These numbers are better than in previous studies of patients with less advanced disease treated with bortezomib alone in which 38 percent responded to the treatment and cancer progressed after an average of 6.22 months.

"The study was not designed to evaluate statistical superiority of the combination of elotuzumab and Velcade, but it does appear to support our preclinical evidence that these two drugs work together," Jakubowiak says.

The researchers will next consider a study to compare the combination of elotuzumab and bortezomib against standard therapy to see if the combination achieves better results.

Further information

Methodology: 28 people with multiple myeloma that had returned or was unresponsive to treatment were given four cycles of elotuzumab and bortezomib (Velcade). Elotuzumab was given twice in a three-week cycle, with increasing doses each time; and a standard dose of bortezomib was given four times during the cycle. Participants with stable disease after the four cycles continued treatment until their cancer progressed. Study participants had all previously received one to three other therapies before being enrolled in this study.

Multiple myeloma statistics: 20,580 Americans will be diagnosed with multiple myeloma this year and 10,580 will die from the disease, according to the American Cancer Society

Additional authors: Don M. Benson, Ohio State University; William Bensinger, Fred Hutchinson Cancer Research Center; David Siegel, Hackensack University Medical Center; Todd Zimmerman, University of Chicago; Ann Mohrbacher, University of Southern California; Paul Richardson, Dana-Farber Cancer Institute; Daniel Afar, Facet Biotech Inc.; Anil Singhal, Facet Biotech Inc.; Kenneth Anderson, Dana-Farber Cancer Institute

Funding: Facet Biotech and Bristol-Myers Squibb Company

Reference: American Society of Clinical Oncology Annual Meeting, June 4-8, 2010, Chicago, Abstract No. 8003


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "New myeloma drug shows promise in early testing." ScienceDaily. ScienceDaily, 9 June 2010. <www.sciencedaily.com/releases/2010/06/100607151322.htm>.
University of Michigan Health System. (2010, June 9). New myeloma drug shows promise in early testing. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2010/06/100607151322.htm
University of Michigan Health System. "New myeloma drug shows promise in early testing." ScienceDaily. www.sciencedaily.com/releases/2010/06/100607151322.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com
West Africa Gripped by Deadly Ebola Outbreak

West Africa Gripped by Deadly Ebola Outbreak

AFP (July 28, 2014) The worst-ever outbreak of the deadly Ebola epidemic grips west Africa, killing hundreds. Duration: 00:48 Video provided by AFP
Powered by NewsLook.com
Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins